Compare Adobe Systems Inc (ADBE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs TG Therapeutics Inc — how do they compare? Adobe Systems Inc trades at $258.56 (market cap $104.82B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Adobe Systems Inc is far larger — about 13.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | TGTX | |
|---|---|---|
Market Cap | $104.82B | $7.64B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $59.06 |
52-Week Low | $193.41 | $26.94 |
Enterprise Value | $106.26B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $256.30, down 6.1% on the day amid broader tech sector weakness. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 versus $5.82 expected. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $252. Revenue grew to $23.77B in 2025 with impressive 28.69% net margins.
Adobe presents a compelling value opportunity trading below analyst consensus targets despite AI competition concerns. The company's robust cash flow generation and market leadership in creative software support long-term growth, though investor sentiment remains cautious due to CEO transition and AI disruption risks. Wall Street maintains a buy-heavy rating with $248.86 average price target.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
